Physician profile
Patrick J Bushard
NPI 1306998448
$3,898.45
in general payments reported to CMS, 2019-2025
38 companies · $317 in 2025
The $317 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $463 · 2020: $65.59 · 2021: $158 · 2022: $811 · 2023: $294 · 2024: $1,789 · 2025: $317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,383 · Education: $17.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,383.18 |
| Education | $17.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $885.29 | 2021-2025 | Botox, Ubrelvy, Qulipta |
| Novartis Pharmaceuticals Corporation | $492.84 | 2019-2025 | |
| Mdd US Operations, LLC | $285.80 | 2022-2024 | Gocovri, Apokyn, Gocovri |
| Lilly USA, LLC | $215.62 | 2022-2024 | Emgality, Reyvow, Amyvid |
| Ucb, INC. | $175.01 | 2019-2025 | Fintepla, Nayzilam, Rystiggo |
| Penumbra, INC. | $147.59 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $145.57 | 2022 | |
| Pfizer INC. | $133.08 | 2024 | |
| Csl Behring | $131.33 | 2022-2024 | Hizentra |
| Celgene Corporation | $106.62 | 2022-2024 | Zeposia |
| Biogen, INC. | $105.73 | 2021-2025 | Tysabri, Vumerity |
| Neurocrine Biosciences, INC. | $104.30 | 2022-2024 | Ingrezza |
| Lundbeck LLC | $78.66 | 2021-2025 | Vyepti |
| Boston Scientific Corporation | $73.99 | 2024-2025 | Vercise |
| Acadia Pharmaceuticals INC | $71.69 | 2021-2024 | Nuplazid |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $66.59 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $52.47 | 2024 | Austedo Xr |
| Scilex Pharmaceuticals INC. | $51.10 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $50.95 | 2024 | Rexulti |
| Abbott Laboratories | $47.60 | 2024-2025 | Infinity |
| Kyowa Kirin, INC. | $42.44 | 2023-2024 | Nourianz |
| Allergan, INC. | $41.90 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $40.82 | 2022-2024 | |
| Medtronic USA, INC. | $40.59 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $38.66 | 2024 | Ponvory |
| Merz Pharmaceuticals, LLC | $35.22 | 2024 | Xeomin |
| Neurelis, INC. | $33.52 | 2022 | |
| Genentech USA, INC. | $30.32 | 2024 | Enspryng, Ocrevus |
| Astrazeneca Pharmaceuticals LP | $26.52 | 2024 | Andexxa |
| Emd Serono, INC. | $23.93 | 2019 | |
| Medtronic, INC. | $19.88 | 2024 | Percept PC Brainsense |
| Supernus Pharmaceuticals, INC. | $17.83 | 2019 | |
| Adamas Pharmaceuticals, INC. | $17.68 | 2021 | |
| Argenx US, INC. | $14.03 | 2022 | |
| Janssen Pharmaceuticals, INC | $14.02 | 2022 | |
| Arbor Pharmaceuticals, INC. | $13.70 | 2019 | |
| Upsher-Smith Laboratories LLC | $13.40 | 2021 | |
| Impel Pharmaceuticals INC. | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Bushard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.